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SUMMARY

Membrane contact sites are recognized as critical means of intercompartmental
communication. Here, we describe a protocol for engineering and validating a
synthetic bridge between the inner and outer mitochondrial membranes to support functioning of the endogenous mitochondrial contact site and cristae organizing system (MICOS). A chimeric protein, MitoT, is stably expressed in cultured
mammalian cells to bridge the mitochondrial membranes. This approach can be a
valuable tool to study the function of the MICOS complex and associated proteins.
For complete details on the use and execution of this protocol, please refer to
Viana et al. (2021).
BEFORE YOU BEGIN
This paper describes a step-by-step protocol for designing and expressing a synthetic chimeric protein to support the stability of mitochondrial intermembrane contacts. The MICOS complex is a
multi-subunit protein complex that connects the inner mitochondrial membrane to the outer membrane and helps in maintaining mitochondrial architecture and function (Harner et al., 2011; Hoppins
et al., 2011; Pfanner et al., 2014; Rabl et al., 2009; Van der Laan et al., 2016; Wollweber et al., 2017).
The absence or reduced functionality of the MICOS complex or related proteins disrupts mitochondrial architecture, leading to mitochondrial dysfunction (Alkhaja et al., 2012; Harner et al., 2011;
Head et al., 2011; Hoppins et al., 2011; John et al., 2005; Rabl et al., 2009). To mitigate such undesirable scenarios, we designed a mammalian chimeric protein designated MitoT to support the
MICOS complex and mitochondrial intermembrane contacts.
MitoT is a first-in-class 435 amino acid-long synthetic protein that consists of four defined domains.
The N-terminal portion of the protein contains a 161 amino acid-long N-terminal region of the inner
mitochondrial membrane-anchored SCO1 protein, which includes the protein’s mitochondrial targeting sequence. This segment is followed by an Escherichia coli LacI protein-derived 12 amino
acid-long unstructured linker region connected to a C-terminal moiety harboring 24 amino acid residues of the outer mitochondrial transmembrane segment of the mitochondrial import receptor protein TOMM20 and a cytosol-exposed eGFP tag.
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The MitoT fusion protein not only augments the function of the MICOS complex but – owing to
the presence of the eGFP tag – provides a handle to visualize the effect on mitochondrial architecture. The MitoT fusion protein is inspired by a previous study in the Saccharomyces cerevisiae yeast genetic model to compensate for MICOS depletion (Aaltonen et al., 2016). The
Viana et al. study (Viana et al., 2021) used this strategy in mammalian cells to unravel the functional interaction between OMA1 metallopeptidase and the MICOS complex. Although the
exact mechanism of how MitoT works to stabilize MICOS remains to be investigated, our results
suggest a model whereby MitoT forms stable bridges between the outer (OM) and the inner
boundary (IBM) membranes, thus stabilizing labile MICOS complex-mediated intermembrane
OM-IBM contacts. The MitoT synthetic protein can be further modified as per intended for
experimental purpose and scientific questions. The strengths of the present protocol include
a novel combination of experiments designed and optimized to study first-in-class synthetic
chimeric protein that is able to support the stability of mitochondrial intermembrane contacts
in mammalian mitochondria.
Prepare buffers, media
Timing: 0.5–2 h
Prepare standard cell culture media, if needed.
Note: 500 mL of media is sufficient for the entire experiment.
Obtain or thaw cells
Timing: 2 days
Obtain, prepare, or thaw cells as needed.
Cell culture
1. Cell revival.
a. Take out frozen MEF cells from liquid nitrogen storage container and revive as per standard
revival protocol.
Note: This protocol is described for mouse embryonic fibroblasts (MEFs) isolated as in Quiros
et al., 2012 (Quirós et al., 2012). The protocol can be applied to other mammalian cell lines.
Note: Ensure there are sufficient cell numbers to stain, seed, and backfill at appropriate time
points.
Note: A minimum of 200,000 MEF cells (passage 2–4) per well in a 6-well plate is recommended. Cell numbers must be adjusted if using a different size well, cell culture plate, or cell
line.
Note: A coated culture dish may be required for certain cell lines. Use coating material according to literature for specific cells of interest.
b. Transfer cell suspension into a T25 cell culture flask containing 5 mL of prewarmed FBS-containing DMEM media and mix well to ensure uniform distribution across the culture flask.
c. Allow cells to grow overnight (12–16 h) in a CO2 incubator at 5% CO2 and 37 C.
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KEY RESOURCES TABLE

REAGENT or RESOURCE

SOURCE

IDENTIFIER

ATCC

Cat# 68233

Bacterial and virus strains
Escherichia coli DH5a competent cells
Chemicals, peptides, and recombinant proteins
Ampicillin

AMRESCO

Cat# 0339

G-418

US Biological

Cat# 108321-42-2

QIAquick gel extraction kit

QIAGEN

Cat# 28706

QIAquick spin miniprep kit

QIAGEN

Cat# 27106

Plasmid midi kit

QIAGEN

Cat# 12143

Luria Bertani Agar

Millipore

Cat# MP113002032

Luria Bertani Broth Miller

US Biological

Cat# L1520

Gel/PCR Purification kit

QIAGEN

Cat# 28004

BamHI-HF restriction enzyme

NEB

Cat# R3101S

EcoRI-HF restriction enzyme

NEB

Cat# R3136S

T4 DNA Ligase enzyme

Thermo Fisher Scientific

Cat# EL0011

103 T4 DNA Ligase buffer

Thermo Fisher Scientific

Cat# B69

Lipofectamine 3000 reagent

Thermo Fisher Scientific

Cat# L3000015

Hoechst 33342

Invitrogen

Cat# H3570

MitoTrackerTM DeepRed FM

Thermo Fisher Scientific

Cat# M22426

FluroBrite DMEM medium

Thermo Fisher Scientific

Cat# A1896702

RNaseZap RNase decontamination solution

Thermo Fisher Scientific

Cat# AM9782

DMEM-High Glucose

HyClone

Cat# SH30243.01

FBS

HyClone

Cat# SH30396.03

Pen/Strep Mix

HyClone

Cat# 15070063

PBS (calcium, magnesium free)

HyClone

Cat# SH30256.FS

Trypsin-EDTA

HyClone

Cat# SH30236.02

Opti-MEM I medium

Gibco

Cat# 31985070

Phusion Hot Start II High-Fidelity PCR Master Mix

Thermo Fisher Scientific

Cat# F565L

Sodium cacodylate trihydrate

Electron Microscopy Sciences

Cat# 12300

Carbonyl cyanide m-chlorophenyl hydrazone (CCCP)

Sigma-Aldrich

Cat# C2759

Glutaraldehyde (50%)

Electron Microscopy Sciences

Cat# 16320

Agarose, low melting temperature

Bio-Rad

Cat# 162-0017

Osmium tetroxide (4%)

Electron Microscopy Sciences

Cat# 19170

Lead citrate trihydrate

Electron Microscopy Sciences

Cat# 17810

Uranyl acetate

Electron Microscopy Sciences

Cat# 22400

Spurr, Low Viscosity Embedding kit

Electron Microscopy Sciences

Cat# 14300

EMS grid 200 mesh, Nickle

Electron Microscopy Sciences

Cat# EMS-200-Ni

Double-end molds

Ted Pella

Cat# 10590

Nuclease-free water

Thermo Fisher Scientific

Cat# AM9937

SuperscriptTM IV first-strand synthesis system

Thermo Fisher Scientific

Cat# 18091050

HEPES

Sigma-Aldrich

Cat# 54457

D-Sorbitol

Sigma-Aldrich

Cat# S1876

Sucrose

Sigma-Aldrich

Cat# S0389

Ethylenediaminetetraacetic acid (EDTA)

Sigma-Aldrich

Cat# E9884

Mouse Embryonic Fibroblasts, Wild Type

Gift from C. Lopez-Otin
(U. Oviedo), Quirós et al. (2012)

N/A

Mouse Embryonic Fibroblasts, OMA1_KO

Gift from C. Lopez-Otin
(U. Oviedo), Quirós et al. (2012)

N/A

Eurofins (Viana et al., 2021)

N/A

Experimental models: Cell lines

Oligonucleotides
Fwd BamHI-SCO1 primer
50 AAAGGATCCATGGCGATGCT
GGTCCTAGTACCC-30

(Continued on next page)
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Continued
REAGENT or RESOURCE

SOURCE

IDENTIFIER

Rev SCO1-LacI primer
50 GACATCGTATAACGTTACT
GGTTTCTTGACGTGCTTCATTCCAGC-30

Eurofins (Viana et al., 2021)

N/A

Fwd LacI TOMM20 primer
50 AGTAACGTTATACGATGTCGCAG
AGATGGTGGGTCGGAACAGCGC-30

Eurofins (Viana et al., 2021)

N/A

Rev TOMM20-His-EcoRI primer
50 CAAGAATTCGTGATGGTGATGGTG
ATGGAAGTAGATGCAGTACCCA-30

Eurofins (Viana et al., 2021)

N/A

Addgene

Cat# 13031; RRID: Addgene_13031

ImageJ Software

NIH (Schindelin et al., 2012)

https://imagej.net/software/
fiji/downloads version 1.53h

Microsoft Excel 365

Microsoft Inc.

https://www.microsoft.com/
en-us/microsoft-365

FlowJo 10

FlowJo Inc.

https://www.flowjo.com/
solutions/flowjo/downloads

Recombinant DNA
pcDNA3-eGFP
Software and algorithms

Other
35 mm No. 1.0 glass bottom dishes

MatTek Corp.

Cat# P35G-1.0-14-C

0.2 mm Filter
FACSCalibur II

Fisherbrand
BD Biosciences

Cat# 09-720-511
N/A

Cytek DxP10 flow cytometer

Cytek Biosciences

N/A

Nikon A1R-Ti2 confocal microscope system

Nikon Inc.

N/A

Countess automated cell counter
Leica UC7 ultramicrotome

Thermo Fisher Scientific
Leica microsystems

Cat# C10281
N/A

Hitachi H7500 transmission electron microscope

Hitachi

N/A

Vacuum Oven

Thermo Fisher Scientific

Cat# 3618-1CE

T100 Thermal cycler
Beckman DU-640 UV-Vis spectrophotometer

Bio-Rad
Beckman

N/A
N/A

MATERIALS AND EQUIPMENT
LB agar plates containing ampicillin antibiotic
Reagent

Final concentration

Amount/volume

Premixed LB Agar powder

13

37 g

Ultrapure water

N/A

Adjust to 1 L

Ampicillin

100 mg/mL

1 mL

Total

1L

Antibiotic added LB agar plates can be stored at 4 C for 2–3 weeks.

Note: Autoclave LB agar media and cool down to 45 C–50 C before adding ampicillin.

LB broth containing ampicillin antibiotic
Reagent

Final concentration

Amount/volume

Premixed LB broth powder

13

25 g

Ultrapure water

N/A

Adjust to 1 L

Ampicillin

100 mg/mL

1 mL

Total

1L

Note: Autoclaved LB broth can be stored at room temperature (20 C–22 C) for 1–2 months.
Add ampicillin just before use.
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Note: Autoclave LB broth and cool down to room temperature (20 C–22 C) before adding
ampicillin.

FBS-containing DMEM-high glucose medium
Reagent

Final concentration

Amount/volume

DMEM-high glucose media

13

445 mL

FBS

10%

50 mL

P/S antibiotic solution

13

5 mL

Total

500 mL

Note: FBS and antibiotic-containing DMEM can be stored at 4 C for 1 month.

MTE buffer
Reagent

Final concentration

Amount/volume

1 M HEPES, pH 7.6

20 mM

2 mL

1 M Sorbitol

220 mM

22 mL

1 M Sucrose

70 mM

7 mL

0.5 M EDTA

1 mM

Total

200 mL
100 mL

Note: Always prepare fresh before use.

Alkaline sodium bicarbonate solution
Reagent

Final concentration

Amount/volume

Sodium bicarbonate (Na2CO3)

0.1 M

106 mg

Ultrapure water

N/A

Total

Adjust to 100 mL
100 mL

Adjust to pH 7.5 and 11.5 with 1N NaOH.

Note: Always prepare fresh before use.

TEM wash buffer
Reagent

Final concentration

Amount/volume

Sodium cacodylate

100 mM

21.4 g

Ultrapure water

N/A

Total

Adjust to 1 L
1L

Adjust to pH 7.4 with 1N HCl.

Note: Always prepare fresh before use.

2.5% Glutaraldehyde fixing solution
Reagent

Final concentration

Amount/volume

Glutaraldehyde (50%)

2.5%

0.5 mL

TEM wash buffer

100 mM

Total

9.5 mL
10 mL

STAR Protocols 3, 101454, September 16, 2022
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Note: Always prepare fresh before use.

1% Osmium tetroxide solution
Reagent

Final concentration

Amount/volume

Osmium tetroxide (4%)

1%

2.5 mL

Ultrapure water

N/A

7.5 mL

Total

10 mL

Note: Prepare 1 day before use in a brown glass bottle and store at 4 C.

Spurr’s epoxy solution
Reagent

Final concentration

Amount/volume

Vinyl cyclohexene dioxide (ERL-4221)

22.3%

9 mL

Diglycidyl ether of polypropylene glycol (D.E.R. 736)

17.3%

7 mL

Nonenyl succinic anhydride (NSA)

59.5%

24 mL

N,N-dimethylethanolamine (DMAE)

0.74%

Total

0.3 mL
40.3 mL

Note: Combine all the reagents into a flask and mix by shaking and swirling.
Note: Always prepare fresh before use.

1% Uranyl acetate solution
Reagent

Final concentration

Amount/volume

Uranyl acetate

1%

0.5 g

Ultrapure water

N/A

Total

49.5 mL
50 mL

Note: Prepare 1 day before use and store at 4 C.

1% Lead citrate solution
Reagent

Final concentration

Amount/volume

Lead citrate

1%

0.1 g

Ultrapure water

N/A

Up to 10 mL

Add 3 drops of 10 N NaOH.
Total

10 mL

Note: Prepare 1 day before use and store at 4 C.

STEP-BY-STEP METHOD DETAILS
Prepare vector
Timing: 2–3 days
This section describes steps to construct the MitoT expression vector. The vector is universal and
should be readily transferable between mammalian cell lines.
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Day 1: Cell harvesting, RNA isolation, and cDNA preparation
Timing: 2 h for step 1
Timing: 1 h for step 2
1. Cell harvesting and RNA isolation.
a. Harvest 5 million cells/sample as per standard cell harvesting protocol.
CRITICAL: Prior to starting RNA isolation, clean workbench, pipettes, and vial stands
with RNaseZap reagent. Use RNase-free polypropylene tips and vials.
b. Add TRIzol reagent to the cell pellet (1 mL per 5 3 106 cells).
Note: The volume of TRIzol reagent depends on the cell number. Refer to product manual to
determine appropriate TRIzol volume according to cell number.
c. Homogenize cells by vigorous pipetting 10 times.
Note: RNA is stable in TRIzol reagent. Therefore, samples can be stored at this step at 20 C
for further use.
d. Add 0.2 mL chloroform to the homogenized cell suspension.
Note: Handle chloroform under fume hood and use polypropylene tips or glass pipette for
aspiration.
e. Shake tube vigorously or vortex for 15 s and incubate at room temperature (20 C–22 C) for
2–3 min.
f. Centrifuge at 12,000 g for 15 min at 4 C.
g. Aspirate the upper, colorless aqueous phase into a separate vial.
CRITICAL: Be very careful when removing the upper layer; do not aspirate or disturb the
middle white ring-like layer. Approximately 400 mL of aqueous phase can be easily aspirated out. Use a 200-mL pipette instead of a 1-mL pipette to minimize the chances of middle layer aspiration.
h. Add 280 mL (70% volume of the aspirated aqueous phase) of isopropanol, and mix by gently
inverting the tube. Incubate for 10 min at room temperature (20 C–22 C).
i. Centrifuge at 12,000 g for 30 min at 4 C.
j. Carefully remove the supernatant and wash the pellet twice with 1 mL of 75% ethanol (room
temperature- 20 C–22 C) by centrifuging at 7,500 g for 5 min at 4 C.
Note: Pellet is usually not readily visible and loosely attached to tube’s wall. About 20–30 mL
of supernatant can be left to prevent the loss of RNA pellet during aspiration.
k. After the final ethanol washing step, remove supernatant completely.
l. Air dry the pellet for 5 min at room temperature (20 C–22 C).
Note: Repeatedly monitor the evaporation of ethanol. As soon as the pellet is dry, proceed
to the next step.
CRITICAL: Over-drying of RNA pellet will reduce RNA solubility and thus the overall yield.

STAR Protocols 3, 101454, September 16, 2022
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m. Dissolve RNA in 30 mL of RNase-free water by gentle pipetting and incubate for 5 min
at 55 C.
Alternatives: Diethyl pyrocarbonate (DEPC)-treated water can be used if commercial RNasefree water is not available.
n. Determine RNA concentration and quality using nanodrop or UV-Vis spectrophotometer at
260 and 280 nm wavelengths.
Note: A good quality RNA prep has a l260/280 ratio of 2.0.
Alternatives: RNA quality and integrity can be checked by separating the RNA of interest in a
denaturing agarose gel.
CRITICAL: Following resuspension in water, RNA becomes highly prone to degradation
by RNase. From this step onwards, keep RNA on ice and avoid multiple freeze-thawing cycles. For long term storage, store the samples at 80 C.
Note: If possible, try to prepare cDNA on the same day as RNA isolation to minimize freezing
and thawing of RNA samples.
2. cDNA preparation.
Use SuperscriptTM IV (SSIV) first-strand cDNA synthesis system for cDNA synthesis.
Note: Preset PCR machine at 65 C before starting the experiment.
Note: Keep all the PCR tubes and reagents on ice.
a. Prepare RNA-primer mix by adding 100 ng-2 mg RNA, 1 mL of Oligo-DT primer and 1 mL of
dNTPs mix.
b. Adjust the final volume to 11 mL by adding RNase-free water.
c. Mix and briefly centrifuge the mixture.
d. Incubate for 5 min at 65 C and keep on ice for 1 min immediately after.
Note: Before proceeding to the next step, vortex and briefly centrifuge 53 SSIV reverse
transcriptase buffer and heat PCR machine to 50 C. Also heat a water bath or heat block
to 80 C.
e. Prepare reverse transcriptase mix by adding 4 mL of 53 SSIV buffer, 1 mL 100 mM DTT, 1 mL of
ribonuclease inhibitor, and 1 mL of SSIV reverse transcriptase enzyme.
CRITICAL: DTT is a toxic chemical and needs to be handled with caution. It gets oxidized
easily in the presence of air and is unstable at room temperature (20 C–22 C). It should be
stored at 20 C in small aliquots.
f.
g.
h.
i.

Add freshly prepared reverse transcriptase mix to RNA-primer mix.
Incubate combined reaction mixture for 10 min at 50 C.
Heat-inactive the reverse transcriptase by incubating for 10 min at 80 C.
Add 2 units of RNase H and incubate for 20 min at 37 C.

Note: Produced cDNA is stable and can be stored at 20 C for future use.
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Figure 1. Design and cloning of MitoT construct
(A) Relevant indicated fragments of the IM-resident SCO1 and OM-residing TOMM20 proteins were amplified individually by overlap extension PCR strategy. In the second round of PCR amplifications, the respective amplicons were
used to generate a single recombinant DNA fragment (MitoT) containing indicated portions of SCO1, TOMM20, a

STAR Protocols 3, 101454, September 16, 2022
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Figure 1. Continued
hexa-histidine tag, an unstructured linker region (E. coli LacI sequence), and BamH1 and EcoRI restriction sites at the
5 0 - and 3 0 -flanking ends, respectively.
(B) The MitoT DNA fragment generated by overlap extension PCR and its host pCDNA3-eGFP vector were digested
with BamHI and EcoRI restriction enzymes. The digested fragments were purified and ligated to yield pCDNA3-MitoTeGFP vector.
(C) The E. coli DH5a competent cells were transformed with the resulting pCDNA3-MitoT-eGFP vector and
transformed clones identified by plasmid isolation and restriction digestion. The verified positive clone was further
propagated for endotoxin free plasmid isolation and sequence validation.

Day 2–3: Amplification and cloning of MitoT fragment into pcDNA3-eGFP vector
Timing: 1 day for step 3
Timing: 1 day for step 4
Timing: 1 day for step 5
3. PCR amplification and digestion of MitoT fragment.
Take 5 mM of each primer pair, prepare PCR master-mix, and perform overlap extension PCR as follows (Figure 1A).
a. Reaction 1:
i. Use 10 ng of cDNA and the primers Fwd BamHI-SCO1 and Rev SCO1-LacI.
ii. Follow the protocol provided by Phusion Hot Start II High-Fidelity PCR Master Mix with
68 C setting for annealing temperature.
iii. Following PCR amplification, separate the samples on a 1% agarose gel.
iv. Observe ethidium bromide-stained relevant DNA bands under a transilluminator and cut
out the 370 bp-fragment from the gel.
Note: Always use a fresh scalpel/blade for gel cutting.
CRITICAL: Long UV exposure is harmful for both the DNA in the agarose gel and the
researcher. Use protective wear to protect eyes and body. Quickly make cuts around
the amplified band and switch off the transilluminator.
v. Purify the amplicon by following the gel extraction protocol as per kit manual.
b. Reaction 2:
i. Use 10 ng of cDNA and the primers Fwd LacI-TOMM20 and Rev TOMM20-His-EcoRI.
ii. Follow the manufacturer’s protocol on using Phusion Hot Start II High-Fidelity PCR Master
Mix with 68 C for the annealing temperature.
iii. Following PCR amplification, separate the samples on a 1.5% agarose gel.
iv. Observe relevant DNA bands under a transilluminator and excise the 115-bp fragment
from the gel.
v. Purify the amplicon by following the gel extraction protocol as per kit manual.
c. Reaction 3:
i. Use an equal amount of the PCR products from the Reactions 1 and 2 and the primers Fwd
BamH1-SCO1 and Rev TOMM20-His-EcoRI.
Note: We suggest using 1 ng of each product for this reaction.
ii.

Follow the manufacturer’s protocol on using Phusion Hot Start II High-Fidelity PCR Master
Mix with 68 C for the annealing temperature.
iii. Following PCR amplification, separate the samples on a 1% agarose gel.

10
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iv.

Observe relevant DNA bands under a transilluminator and cut the 468-bp fragment from
the gel. This final amplicon constitutes the complete MitoT DNA fragment.
v. Purify the amplicon by following the gel extraction protocol as per kit manual.
vi. Digest the PCR product from Reaction 3 using BamHI and EcoRI restriction enzymes.
vii. Purify the digested fragment using the QIAquick gel extraction kit per manufacturer’s protocol.
viii. Determine the purity and concentration of the purified MitoT DNA fragment using a UVVis spectrophotometer.
4. Amplification and digestion of pcDNA3-eGFP vector (Figure 1B).
a. Transform E. coli DH5a competent cells with the pcDNA3-eGFP plasmid as per standard protocol.
b. Inoculate a single colony in 5 mL of LB media containing ampicillin and incubate for 8 h at
37 C.
c. Take 100 mL of grown starter culture and inoculate in 100 mL of LB media containing ampicillin.
d. Pellet the cells by centrifuging at 5,000 g for 15 min at room temperature (20 C–22 C).
e. Isolate the plasmid using a plasmid midi prep endotoxin-free kit per manufacturer’s instructions.
f. Quantitate plasmid concentration using a UV-Vis spectrophotometer.
g. Digest the plasmid using BamHI and EcoRI restriction enzymes using standard NEB digestion
protocol.
h. Separate the digested plasmid on a 1% agarose gel, cut out the desired band, and purify it
using a gel purification kit.
i. Determine the purity and concentration of the purified digested plasmid using a UV-Vis spectrophotometer.
5. Ligation of the MitoT DNA fragment and digested pcDNA3-eGFP vector.
a. Set up ligation reaction (Figure 1B).
Vector only control reaction

Ligation reaction

Digested pcDNA3-eGFP vector

100 ng

100 ng

Digested MitoT insert

–

20 ng

103 T4 DNA Ligase Buffer

2 mL

2 mL

T4 DNA ligase

1 mL

1 mL

Nuclease Free Water

Adjust volume to 20 mL with ddH2O

Adjust volume to 20 mL with ddH2O

b. Incubate for 1 h in a thermal cycler at 16 C.
Alternatives: The reaction can also be done by incubating the reaction mix overnight (12–
16 h) at 4 C.
Alternatives: The construct can be synthesized using other molecular biology approaches
such as the Gibson assembly approach.
c. Transform 5 mL of ligation mix into E. coli DH5a competent cells (Figure 1C).
d. Select single colonies and inoculate in 5 mL LB containing ampicillin in a glass tube.
e. Following 16 h incubation at 37 C, pellet the cells by centrifuging at 5,000 g for 15 min at room
temperature (20 C–22 C) and isolate plasmid for analysis.
f. Digest isolated plasmid with EcoRI and BamHI restriction enzymes and electrophoretically
separate the digest on a 1% agarose gel to confirm the presence of the MitoT insert (468bp band).
g. Validate the sequence of the MitoT construct by DNA sequencing (Figure S1; Data S1;
Table S1).
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h. Inoculate 5 mL of LB-Ampicillin medium with an E. coli clone harboring confirmed MitoT
plasmid.
i. After 8 h incubation at 37 C, measure the OD600 of the initial inoculum, and inoculate 100 mL
in 100 mL LB medium containing ampicillin antibiotic.
j. Pellet the cells by centrifuging at 5,000 g for 15 min at room temperature (20 C–22 C).
k. Isolate plasmid using a midiprep endotoxin-free plasmid purification kit per manufacturer’s instructions.
l. Determine the purity and concentration of isolated plasmid using a UV-Vis spectrophotometer.
Cell culture, transfection, and FACS-based selection
Timing: 9–10 days
Timing: 9–10 days for step 6
Timing: 2 h for step 7
The following steps provide details about transfection of the pcDNA-MitoT-eGFP vector in MEF cells
followed by antibiotic selection and FACS-based selection of GFP-expressing cells (Figure 2).
6. Transfection and selection.
a. Twenty-four hours prior to transfection, seed 5 3 105 cells per well into 6-well plate or 35 mm
dish.
b. Transfect the cells with 1 mg of control vector pcDNA3-eGFP and pcDNA3-MitoT-eGFP
plasmid using Lipofectamine 3000 transfection reagent.
c. Change the media after 16 h of transfection.
d. At 48 h post-transfection, start the selection of G418-resistant clones using 2 mg/mL of G418.
Note: Before treatment, an individual effective concentration of G418 needs to be determined for every cell line used. It is essential to make a titration curve to identify the lowest concentration of antibiotic that kills 90% of wildtype cells within 3–5 days.
e. Keep the cells under antibiotic pressure for at least 7 days, replacing the medium every 2 days.
f. Confirm expression and establishment of a MitoT-expressing stable cell line by fluorescence
microscopy or by western blotting using anti-GFP antibody.
7. FACS sorting.
a. Harvest the cells and make a cell suspension with approximately 5 3 106 cells per mL.
Note: Use Ca2+- and Mg2+-free PBS to prevent the formation of cell aggregates.
CRITICAL: To decrease the aggregate formation and maintain cell viability, supplement
PBS with 1% FBS, 5 mM EDTA, and 25 mM HEPES, pH 7.4.
b.
c.
d.
e.

Sort the MitoT-GFP-positive cells using a 488-nm laser with a 530/30 bandpass filter.
Use 100 mm nozzle size, 20 psi for fluid sheath pressure, and 6,000 events/sec maximum rate.
Use non-transfected cells to determine proper threshold gate for eGFP-negative cells.
Sort the cells in 10% FBS-containing DMEM medium containing 20 mM HEPES, pH 7.4.

CRITICAL: In our experiments using OMA1 knockout MEF cells transfected with pcDNA3MitoT-eGFP, we observed two populations of GFP-expressing cells (Figure 2). The population of brighter cells with eGFP intensity greater than 104 on the histogram (referred to as
GFPhi) results from protein localization error. In these cells, most of the eGFP signal was in
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Figure 2. Generation and isolation of MitoT-expressing cells
Mouse embryonic fibroblasts were transfected with pCDNA3-MitoT-eGFP vector, cultured and harvested as
explained in the text. Antibiotic-resistant cells were then profiled and processed by FACS. Importantly, FACS profiling
revealed two distinct cell populations with low (GFPlo) and high (GFPhi) eGFP expression. Cells from the GFPlo group
were confirmed to be the desired cell population and collected for further analyses.

the cytoplasm. The population of cells with GFP intensity close to 103 (referred to as GFPlo)
displayed eGFP co-localization with mitochondria. These values can vary among different
cell types and FACS instruments. It is important to carefully analyze isolated cells under a
fluorescence microscope to confirm proper subcellular localization of the eGFP signal.
f. After sorting and validating the cells, centrifuge cells at 300 g for 10 min at room temperature
(20 C–22 C), remove the medium, and transfer the cells to the 10% FBS-containing DMEM
medium and dish containing 2 mg/mL of G418.
CRITICAL: The cells must always be kept in G418 to ensure the retention of the MitoTeGFP construct.
Clone selection
Timing: 7–10 days
This section describes the process of stable clone generation of FACS-sorted GFP positive cells by
antibiotic selection. This is a final step of clone selection by antibiotic treatment after FACS-sorting
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Figure 3. Selection of stable MitoT-expressing clones
The selected cells were cultured under antibiotic selective conditions to produce stable clones of the MitoT-eGFPexpressing cells. The surviving clones were preserved and used in subsequent imaging studies.

of the GFPlo MEF cell population (Figure 3). It is expected that under antibiotic selection pressure
the surviving cells should harbor stably integrated MitoT-eGFP expression construct.
8. Culturing sorted cells.
a. Re-seed the FACS-sorted cells in a 6-well plate.
b. Add 10% FBS-containing DMEM medium containing 2 mg/mL of active G418 antibiotic.
c. Change the medium every other day with antibiotic selection.
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Figure 4. Visualization of MitoT-GFP expression, its colocalization with mitochondria, and ultrastructure analysis
(A) Collected MitoT-eGFP-expressing cells (GFPhi and GFPlo) were treated with MitoTracker Deep Red dye (MTR) and
live-imaged by confocal fluorescent microscopy to ensure proper mitochondrial localization of the MitoT-eGFP
synthetic protein. Scale bar, 20 mm.
(B) Representative TEM images of OMA1 KO and OMA1 KO_MitoT cells that have been treated with an uncoupler
CCCP or left untreated. Induced expression of MitoT in OMA1 KO cells mitigates abnormal mitochondrial cristae
morphology that becomes visible upon uncoupling. Scale bar, 0.4 mm. Images adopted from Viana et al. (2021).

d. After 7 days culturing under the selective conditions, reconfirm plasmid retention by checking
for the presence of eGFP signal under a fluorescence microscope.
e. Trypsinize and re-seed surviving cells into a fresh 6-well plate.
f. Allow cells to grow to 90% confluency.
g. Cryofreeze some of the cells for future use.
h. Seed the cells into glass-bottom 35-mm dishes.
Live cell imaging by confocal fluorescence microscopy
Timing: 2–3 h
This section describes steps to prepare samples for fluorescence imaging. Set up a confocal fluorescence microscope according to the manufacturer’s instructions prior to sample preparation for
imaging.
9. Live cell imaging (Figure 4A).
a. Prepare a fresh 1 mM stock solution of MitoTracker DeepRed dye in DMSO.
Note: For storage, keep 1 mM MitoTracker DeepRed dye solution at 20 C.
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Dilute the dye at 1:1000 dilution (final working concentration 1 mM) in FluoroBrite DMEM medium.
Remove the culture medium and wash the cells once with 1 mL of 13 PBS.
Add 1 mL of MitoTracker dye-containing medium to the 35-mm dish.
Incubate for 30 min at 37 C.
Remove medium and wash cells twice with 1 mL FluoroBrite DMEM medium only.
Add 1 mL of FluoroBright DMEM medium containing 1:2000 diluted Hoechst 33342 (final
working concentration 5 mg/mL) nuclear staining dye.
h. Incubate for 10 min (protected from light!) and then wash twice with FluoroBright DMEM medium.
i. Add 1 mL of FluoroBrite DMEM medium supplemented with 1% FBS.

b.
c.
d.
e.
f.
g.

Note: Using 1% FBS prevents cell starvation without increasing background fluorescence on
images.
j. Observe cells using 603 oil objective.
k. Use ultraviolet 405 nm solid state laser for Hoechst 33342 excitation, 425–475 nm bandpass
filter for emission and focus the cells according to optimum nuclear staining signal. The
maximum emission wavelength for Hoechst 33342 dye is 461 nm.
Note: For live cell imaging, it is beneficial to use stage top CO2 incubator to minimize cell
stress and to preserve proper mitochondrial morphology.
Note: Hoechst 33342 nuclear stain is used here only to focus cells hence it is optional yet
highly recommended. Pre-focusing the cells using Hoechst signal minimizes the GFP bleaching due to long exposure of laser. Observe eGFP signal using 488 nm solid state excitation
laser and 500–550 nm bandpass emission filter. The maximum emission wavelength for eGFP
protein is 509 nm.
l. For MitoTracker DeepRed imaging, use 640 nm solid state excitation laser and 633–673 nm
emission filter. The maximum emission wavelength for MitoTracker DeepRed is 665 nm.
CRITICAL: If a stage-top incubator for CO2 control is not available, the medium must be
supplemented with 25 mM HEPES buffer, pH 7.4.
Transmission electron microscopy (TEM) imaging
Timing: 4–5 days
This section describes steps of sample preparation and visualization of cristae stabilization by MitoT
using transmission electron microscopy (TEM) (Figure 4B).
10. TEM Imaging.
a. Grow cell lines of interest in a 30-mm culture dish overnight (12–16 h).
b. Treat the cells with 2 mM carbonyl cyanide m-chlorophenyl hydrazone (CCCP) or without
CCCP (mock control: DMSO) for 1 h at 37 C in a CO2 incubator.
c. Trypsinize the cells and wash three times with 500 mL PBS.
d. Count cells using an automated cell counter (Online Automated Cell Counting Protocol) and
pellet 1 million cells for each cell line in question.
Note: Prepare and process 4–5 replicates per cell line being analyzed.
e. Fix with 2.5% glutaraldehyde (prepared in TEM wash buffer) for 1 h at room temperature
(20 C–22 C) and then keep overnight (12–16 h) at 4 C.
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CRITICAL: Prepare fresh fixative immediately before use.
CRITICAL: Glutaraldehyde is a skin and respiratory tract irritant. It should be used in a
fume hood with caution and protective wear.
f. Wash the cells with 500 mL TEM wash buffer 33 5 min at 500 g.
g. Pellet the cells and embed in 1% low-melting agarose.
i. Dissolve 1% low-melting agarose at 65 C in TEM wash buffer.
ii. Add 250 mL lukewarm agarose to the cell pellets, vortex to resuspend and centrifuge at
9,500 g at room temperature (20 C–22 C) for 5 min.
iii. Allow agarose to solidify at 4 C for 3–4 h.
iv. Transfer agarose to a Petri dish using small spoon-scoop spatula and filter forceps. Cut
out a 2-mm block of solidified agarose containing the cell pellet.
h. Post-fix the cells with 1% osmium tetroxide in deionized water for 1 h.
CRITICAL: Osmium tetroxide is a skin and respiratory tract irritant. It should be prepared
and used in a fume hood with caution and protective wear. Prepare and store Osmium tetroxide in amber bottle at 4 C. Osmium tetroxide is a heavy metal and should not be
drained off the sink. Follow institutional guideline for the proper disposal.
i.
j.

Wash the cells with 500 mL deionized water three times for 5 min each time.
Gradually dehydrate agarose block with embedded cells by washing it with 50%, 75%, 95%
(5 min each wash) and 100% ethanol (twice, 10 min each wash).
CRITICAL: Do not allow samples to air dry!

k. Follow below steps to embed the cells:
i. Keep the cell block in a double-end mold and incubate in 1:1 solution of 100% ethanol/
Spurr’s solution for 2 h at room temperature (20 C–22 C).
ii. Incubate in pure Spurr’s solution for 2–3 h at room temperature (20 C–22 C).
iii. Keep for embedding in Spurr’s solution for 24–36 h at 60 C in a vacuum oven.
l. Remove the dried block and trim the edges.
m. Cut 70–90 nm-thick sections using a Leica UC7 ultramicrotome.
n. Place the sections on EM grids and stain with 1% uranyl acetate for 10 min. Rinse thoroughly
(up to 10 times) with double distilled water (ddH20).
o. Stain sections with 1% lead citrate for 5 min. Spot 100 mL of ddH20 at 8 places on a Petri dish
and dip grid 10 times into each spot for washing.
CRITICAL: Uranyl acetate and lead citrate are highly toxic heavy metals and should be
used with utmost care. Do not drain off in sink; follow institutional guideline for proper
disposal of the used solutions.
p. Image at 10,0003 and 25,0003 magnification with a Hitachi H7500 transmission electron
microscope at 80 kV setting. Take 25–30 images for each section.
Mitochondrial isolation and alkaline extraction of mitochondrial proteins
Timing: 1 day
This part briefly describes steps of isolation of MitoT-expressing mitochondria and carbonate extraction of mitochondrial proteins to ensure membrane anchoring of MitoT (Figure 5).
11. Mitochondria Isolation.

STAR Protocols 3, 101454, September 16, 2022

17

ll

OPEN ACCESS

Protocol

Figure 5. Isolation of MitoT-GFP expressing mitochondria and alkaline extraction of mitochondrial proteins
(A) Workflow for isolation of MitoT-expressing mitochondria.
(B) Workflow for alkaline sodium carbonate extraction and fractionation of mitochondrial proteins.
(C) Representative immunoblots of MitoT-eGFP and control mitochondrial proteins at indicated pH or without Na2CO3 treatment (-). These experiments demonstrate
retention of MitoT-eGFP in the extraction-resistant fractions (P), thereby indicating membrane anchoring of the protein. HSPD1 and NDUFA9 were used as controls
for soluble and membrane associated mitochondrial proteins respectively. P = pellet fraction, S = Soluble fraction, T = Total protein (10% of fraction loaded).

a. Remove media, wash the cells with 5 mL 13 PBS and harvest 20 million MitoT-eGFP expressing MEF cells by scraping the cells with a rubber policeman.
Note: Mitochondrial yield may vary depending on the cell type. Users may need to determine appropriate cell number for mitochondria isolation.
b. Pellet down cells at 800 g for 5 min at room temperature (20 C–22 C) and remove supernatant.
c. Resuspend cells in 2 mL pre-chilled MTE buffer per 10 million cells (add 10 mL of 0.2 M PMSF
per mL of MTE buffer just before use).
Note: Use 15 mL tubes containing no more than 6 mL of MTE buffer.
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CRITICAL: Avoid touching the sonicator probe with the walls of plastic tube.
d.
e.
f.
g.
h.

Sonicate for 10 s at 20%–30% of amplitude.
Keep samples on ice for 20 s.
Repeat steps ‘d’ and ‘e’ two more times.
Centrifuge at 2,000 g for 10 min at 4 C.
Recover the supernatant, transfer recovered supernatant to a new tube and centrifuge at
12,000 g for 10 min at 4 C.
i. The pellet formed is the crude mitochondria fraction. Add 500 mL of MTE buffer containing
0.2 M PMSF, resuspend the pellet and aliquot in 50 mL fractions.
j. Determine total protein concentration of mitochondria-enriched fraction using Coomassie
(Bradford) Protein Assay kit.
Note: Flash-freeze crude mitochondrial fractions in liquid nitrogen and store aliquots
at 80 C for later use.
CRITICAL: Liquid nitrogen is a skin, eyes, and respiratory tract irritant. It should be used
with caution and protective wear.
12. Alkaline extraction of mitochondrial proteins.
a. Take 100 mg of mitochondria, pellet the organelles at 12,000 g for 10 min at 4 C, and resuspend pelleted mitochondria in 0.5 mL of 0.1 M alkaline sodium bicarbonate solution, pH 7.5
or 11.5. Use 0.5 mL of ultrapure water for mock-treatment sample.
b. Vortex and incubate samples on ice for 30 min.
c. Transfer samples into 5 mL polycarbonate tubes and adjust volume to 3 mL with 0.1 M sodium bicarbonate or ultrapure water. Ultracentrifuge at 175,000 g for 30 min at 4 C. Keep
obtained pellets on ice for further steps.
d. Take supernatant fraction into a fresh 1.5 mL tubes and precipitate protein using 20% TCA
and 0.07% (w/v) sodium deoxycholate. Incubate these samples on ice for 45 min.
e. Centrifuge at 16,000 g for 10 min at 4 C.
f. Wash the pellet with ice-cold acetone and centrifuge at 16,000 g for 2 min at 4 C. Repeat this
step two times. Air dry the pellet after final wash.
Note: The pellet obtained at step ‘c’ is the insoluble fraction and contains integral proteins, which do not solubilize in alkaline bicarbonate buffer. The soluble proteins are
precipitated by using TCA buffer and obtained as a pellet after TCA precipitation and
centrifugation.
Note: The same soluble pellets containing TCA-precipitated proteins can be pooled together
at this step.
g. Resuspend both pellets obtained at step ‘c’ and step ‘d’ in 10 mL of 0.1M NaOH and perform
standard SDS-PAGE and immunoblotting with relevant antibodies.

EXPECTED OUTCOMES
The present protocol describes the design, synthesis, and application of a synthetic mitochondrial protein, MitoT. This construct bridges the outer and inner mitochondrial membranes and
provides additional stability to the mitochondrial intermembrane contact sites. We used this protocol for MEF cells but recently it has been replicated successfully in U2OS cells (Li et al., 2022).
This construct is useful in situations where mitochondria membrane stability or MICOS function
gets compromised due to absence or mutation in mitochondrial quality control and structural
proteins.
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Figure 1 provides a schematic depiction of MitoT vector design and cloning procedures. The MitoT
fusion protein comprises the N-terminal residues of the inner mitochondrial membrane protein
SCO1, a 12 amino acid-long unstructured linker region, a transmembrane region of the outer mitochondrial membrane protein TOMM20, and an eGFP tag. This fusion construct was synthesized by
an overlap extension PCR approach. The EcoRI and BamHI restriction sites were introduced in the 50 and 30 - regions of the resulting DNA fragment, respectively. The amplified construct was gel-purified
and examined by UV-Vis spectroscopy to assess its concentration and purity. Both the fusion
construct and pcDNA3-eGFP vector were digested with EcoRI and BamHI restriction enzymes and
purified using a PCR purification kit. The resulting DNA fragments were ligated and transformed
into E. coli DH5a chemically competent cells. Transformant colonies were picked up individually
and cultured for subsequent plasmid DNA isolation and insert validation by restriction digestion followed by re-isolation and DNA sequencing of positive plasmid constructs. The positive clones were
then amplified and endotoxin-free purified for further applications.
Figure 2 shows the workflow of MitoT construct transfection in cultured MEF cells and FACS-based
analysis and isolation of transfected cells. The MEF cells were revived and cultured in the indicated
growth medium. The cells were transfected with the control vector (pcDNA3-eGFP) or MitoTharboring plasmid. At 48 h post-transfection, cells were selected in G418 for 1 week. Post selection,
cells were trypsinized and FACS-sorted based on eGFP expression intensity.
Figure 3 depicts the process of stable integration of MitoT vector through antibiotic selection. The
eGFP-positive cells isolated via FACS procedure were re-cultured and treated with gentamycin antibiotic for 7 days. Cells that survived the antibiotic treatment were individually selected and cultured
to obtain stable clones of MitoT-expressing MEFs.
Figure 4 shows microscopy images of MEF cells expressing eGFP vector or MitoT-eGFP. Mitochondria
were stained with MitoTracker Deep Red dye and imaged using a live confocal fluorescence imaging system. The red (MitoTracker) and green (eGFP) signals were merged to demonstrate co-localization. The
representative image shows that MitoT protein specifically localizes to mitochondria. TEM images of
mock or CCCP-treated OMA1 KO MEF cells and OMA1 KO MEF cells expressing MitoT show the effect
of CCCP treatment on cristae morphology. Specifically, the treatment of OMA1 KO cells with CCCP disrupts cristae morphology, whereas this effect is mitigated by MitoT overexpression.
Figure 5 shows the workflow of mitochondrial isolation from MitoT-eGFP expressing cells and subsequent alkaline extraction of mitochondrial proteins to ascertain membrane integration of MitoT.
The representative figure shows immunoblot analyses of fractionated MitoT-eGFP and control mitochondrial proteins demonstrating the resistance of the former to alkaline carbonate extraction,
thereby validating that MitoT is indeed an integral membrane protein.

LIMITATIONS
First, the MitoT has been only successfully tested in OMA1 knockout MEF cells and wild-type U2OS
cells. The broader application of this system remains to be established. For instance, MitoT could be
deployed to study mechanisms of mitochondrial membrane stabilization by many other proteins
including the MICOS subunits. Second, the mechanism of MitoT-mediated cristae stabilization remains incompletely understood. Exactly how the expression of the inner and outer mitochondrial
membrane-bridging polypeptide rescues the complex cristae architecture of mitochondria requires
further investigation. Third, the extent to which MitoT is able to rescue mitochondrial functions also
needs further testing under different stress conditions.
Finally, we used an antibiotic-based selection approach to obtain stable clones of MitoT-expressing
cells, which has a shortcoming of spontaneous reversal of cells to their original phenotype. Using
lentiviral-based vectors may be advantageous for stable clone generation.
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TROUBLESHOOTING
Problem 1
Very little or no GFPlo-cells are observed during the FACS procedure (step 7e).
Potential solution
The concentration of antibiotic used in the screening procedure is essential for obtaining a stable
line of MitoT-expressing cells. Using >2 mg/mL of G418 may be beneficial in accelerating the attainment of stable cells; however, this may also lead to selecting cells with multiple copies of the
plasmid, which would result in MitoT-eGFP overexpression, causing its unwanted accumulation in
the cytosol. It is essential to make a titration curve to identify the lowest concentration of antibiotic
that kills 90% of cells within 3–5 days.
Problem 2
Cell line is not responding to antibiotic treatment or shows a very low recovery of GFP-positive cells
after FACS sorting irrespective of initial transfection efficiency (steps 8d and 7e).
Potential solution
Some immortalized cell lines may contain an endogenous (e.g., neomycin) antibiotic resistance
gene. The presence of such a gene makes the selection of stable cells considerably more challenging. In this case, it is recommended to use vectors harboring different antibiotic resistance
marker genes such as blasticidin or puromycin.
Problem 3
Loss of eGFP signal or plasmid by a presumably stable cell line after a few passages.
Potential solution
Stable cell line generation using this protocol is based on the efficiency of antibiotic selection and
random integration of the gene of interest. Some cell cultures are not very prone to such random
integration and consequently could lose the gene quickly, even under selective pressure conditions.
To circumvent this issue and produce long-lasting stable cell lines, we recommend using vectors that
carry a transposase such as piggyBac, Sleeping beauty, or even lentiviral particles.
Problem 4
Weak adherence of cells to glass-bottom dish (step 9c).
Potential solution
Glass bottom dishes are essentially required for live cell microscopy, but glass is a poor substrate for
cell adherence and some cell lines may detach easily during washing or staining step. Coating glass
surface with appropriate coating material can overcome this issue.
Problem 5
Low mitochondria yield (step 11j).
Potential solution
The mitochondrial yield depends on the cell type and culture media composition. To improve the
mitochondrial yield, more cells can be cultured. Alternatively, culturing cells in 10 mM galactosecontaining media for 48 h before harvesting also increases the cellular mitochondrial content and,
ultimately, mitochondrial yield.
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